Platelet aggregation inhibition with glycoprotein IIb-IIIa inhibitors

Journal of Thrombosis and Thrombolysis

Volumn 11, Issue 2, 2001, Pages 99-110

  Proimos, G ^a  

^a EPWORTH HOSPITAL   (Australia)

Author keywords

GP IIB IIIa inhibitors; Inhibition; Pharmacology; Platelet aggregation

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; CALCIUM ION; CHIMERIC ANTIBODY; CITRATE SODIUM; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; N ACETYLCYSTEINYLASPARAGINYLPROLYLARGINYLGLYCYLASPARTYL(O METHYLTYROSYL)ARGINYLCYSTEINAMIDE CYCLIC 1,9 DISULFIDE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TIROFIBAN; VON WILLEBRAND FACTOR;

ACUTE DISEASE; ARTERY THROMBOSIS; ASSAY; BLEEDING; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CHELATION; CLINICAL TRIAL; CONVALESCENCE; CORONARY ARTERY BYPASS SURGERY; CROSS REACTION; DOSE RESPONSE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNE RESPONSE; LIGAND BINDING; META ANALYSIS; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHARMACODYNAMICS; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; REVIEW; ST SEGMENT ELEVATION; STRUCTURE ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION;

ADENOSINE DIPHOSPHATE; AMINO ACID CHLOROMETHYL KETONES; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CLINICAL TRIALS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; OLIGOPEPTIDES; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEINS; RECEPTORS, THROMBIN; THROMBIN; TYROSINE;

EID: 0034916180     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011216414539     Document Type: Review

References (65)

1. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes
2. Thrombosis in ischemic heart disease
3. Antiplatelet and anticoagulant use after myocardial infarction
4. Interaction of fibrinogen with its platelet receptor as part of a multistep reaction in ADP-induced platelet aggregation
5. The platelet membrane glycoprotein IIb-IIIa complex
6. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets
7. Purification of glycoproteins IIb and III from human platelet plasma membranes and characterization of a calcium-dependent glycoprotein IIb-III complex
8. Calcium binding to human platelet integrin GPIIb/IIIa and to its constituent glycoproteins. Effects of lipids and temperature
9. Calcium cation regulation of glycoprotein IIb-IIIa complex formation in platelet plasma membranes
10. Identity of saturable calcium-binding sites on blood platelets and their involvement in platelet aggregation
11. Calcium regulation of the platelet membrane glycoprotein IIb-IIIa complex
12. Integrins: Versatility, modulation, and signaling in cell adhesion
13. Platelets in cardiovascular thrombosis and thrombolysis
14. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
15. Studies on the mechanism of expression of secreted fibrinogen on the surface of activated human platelets
16. Clinical pharmacology of eptifibatide
17. 3
18. Arg-Gly-Asp: A versatile cell recognition signal
19. Arginyl-glycylaspartic acid (RGD): A cell adhesion motif
20. Structural and functional analyses of the Arg-Gly-Asp sequence introduced into human lysozyme
21. Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions
22. Glanzmann's thrombasthenia: The spectrum of clinical disease
23. Platelets and thrombolytic therapy
24. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
25. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
26. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
27. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial
28. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa
29. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans
30. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty
31. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions
32. Abciximab (c7E3 Fab). A review of its pharmacology and therapeutic potential in ischaemic heart disease
33. Readministration of abciximab: Interim report of the ReoPro readministration registry
34. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
35. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
36. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
37. Abciximab and excessive bleeding in patients undergoing emergency cardiac operations
38. Prophylactic platelet transfusion in abciximab-treated patients requiring emergency coronary bypass surgery
39. 33 integrins
40. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1
41. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri
42. Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms
43. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention
44. INTEGRILIN® (eptifibatide) Injection
45. Tirofiban, a nonpeptide inhibitor of the platelet glycoprotein IIb/IIIA receptor
46. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty
47. Aggrastat® (tirofiban HCl injection)
48. Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group
49. Bleeding time. A guide to its diagnostic and clinical utility
50. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
51. Pharmacology of the intravenous platelet receptor glycoprotein IIb-IIIa antagonists
52. Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation
53. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study
54. Platelet glycoprotein IIb/IIIa receptor blockade with high-dose INTEGRILIN™ in coronary intervention. Results of the PRIDE study
55. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIIa inhibitors in animal models of platelet-mediated thrombosis
56. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian lamifiban study
57. ++ accounts for the sex difference in the aggregation of human platelets in citrated platelet-rich plasma
58. 3 subunit: Cation displacement is involved in ligand binding
59. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
60. Platelet aggregation inhibition with single and double bolus regimens of eptifibatide (Integrilin)
61. Effect of anticoagulation and platelet agonist concentration on the inhibitory activities of GPIIb-IIIa antagonists
62. Differential effects of citrate versus PPACK anticoagulants: Implications for comparing glycoprotein IIb/IIIa inhibitors
63. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
64. Molecular mechanisms of thrombin signaling
65. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function